SAM
PACB icon

Shell Asset Management’s Pacific Biosciences PACB Stock Holding History

Shell Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6,775
Closed -$55K – 1306
2022
Q4 		$55K Sell
6,775
-870
-11% -$7.5K ﹤0.01% 1253
2022
Q3 		$44K Sell
7,645
-1,048
-12% -$6.01K ﹤0.01% 1344
2022
Q2 		$38K Buy
8,693
+182
+2% +$1.11K ﹤0.01% 1373
2022
Q1 		$77K Sell
8,511
-1,223
-13% -$14.1K ﹤0.01% 1320
2021
Q4 		$199K Buy
9,734
+39
+0.4% +$941 ﹤0.01% 1213
2021
Q3 		$248K Sell
9,695
-470
-5% -$13.9K 0.01% 1140
2021
Q2 		$355K Buy
+10,165
New +$296K 0.01% 1061

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Shell Asset Management's PACB Position: Q1 2023 in Review

Shell Asset Management sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 6,775 shares — an estimated $55K sold.

Shell Asset Management first reported a position in PACB in Q2 2021 and held it in 7 quarters. The position peaked at $355K in Q2 2021. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

  • Shell Asset Management reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
  • Shell Asset Management sold 6,775 Pacific Biosciences shares in Q1 2023, an estimated $55K.
  • Shell Asset Management first reported a position in Pacific Biosciences in Q2 2021 and held it in 7 quarters.
  • Shell Asset Management's Pacific Biosciences position peaked at $355K in Q2 2021.
  • 259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Shell Asset Management's 13F filing for Q1 2023, filed 15 May 2023.